4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists, focusing on 2-year follow-up data from the PRISM Phase 2b trial of 4D-150 in neovascular AMD. The presentation is scheduled for July 18, 2026, and materials will be made available on the company's website following the event.
Key figures
- Drug Name
- 4D-150
- Phase Of Trial
- Phase 2b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.